MAPT and Alzheimer disease: Moreover, when numerous authors have pointed out chronic brain inflammation as an early event in AD (Fernández et al., 2008; Rojo et al., 2008; Maccioni et al., 2009), thus; it seems reasonable to hypothesize that VEGFS-c type agonists could ameliorate AD symptoms in late disease stages, or when the amyloid and tau burden in the brain tissue is high enough to overcome the BLS drainage capacity.